India’s Emergence As A Global Biopharmaceutical Player: Aligning CDSCO Guidelines With International Standards For Health Equity

The world of pharmaceuticals is in a state of transformation as biologics - complex drugs derived from living organisms, become increasingly significant for chronic and severe diseases. Despite their transformative impact on patient lives, their exorbitant prices restrict their access. However, a major "patent cliff" from 2022 to 2032, with almost 300 drug patents expiring each year, has set impetus for rapid growth of the biosimilar market. This article explores the changing regulatory landscape of USFDA, EMA, CDSCO and other nations. At the same time, India is gradually escalating the ladder from being a local manufacturer to global player by adopting 2025 guidelines in line with WHO standards, enabling availability of biopharmaceuticals for low- and middle-income nations. This article also discusses the opportunities and challenges in the global uptake of biosimilars. Conclusively, a holistic approach, blending scientific excellence with equity, is needed to ensure access to life-saving drugs for all patients worldwide.